Displaying all 4 publications

Abstract:
Sort:
  1. Cheo SW, Khoo TT, Tan YA, Yeoh WC, Low QJ
    Med J Malaysia, 2020 07;75(4):447-449.
    PMID: 32724015
    Malaria is a parasitic disease that is caused by the Plasmodium parasite. Worldwide, it remains a significant public health problem especially in the Africa region where it contributes to more than 90% of cases and malaria death. However, zoonotic (simian) Plasmodium knowlesi parasite is a widely prevalent cause of malaria in the South East Asian countries. It is known to cause severe human disease due to its 24hour erythrocytic cycles. Thus far, cases of severe falciparum malaria have been reported in asplenic patients. Here, we report a case of severe P.knowlesi malaria in a 51-year-old man who is a postsplenectomy patient.
  2. Yeoh WC, Lee KT, Zainul NH, Syed Alwi SB, Low LL
    Oxf Med Case Reports, 2021 Sep;2021(9):omab081.
    PMID: 34527254 DOI: 10.1093/omcr/omab081
    Emerging evidence suggest that COVID-19 is associated with hypercoagulability, predisposing patients to increase risk of thromboembolism. Anticoagulation is not without its risks of bleeding and decision to initiate anticoagulation should be carefully considered with close monitoring. Spontaneous retroperitoneal hematoma is a rare complication, and there are only a few documented reports implicating anticoagulant or antiplatelet agents as a potential cause. We report a 57-year-old gentleman with COVID-19 pneumonia who developed hypotension on Day 10 of illness while on prophylactic anticoagulation. Computed tomography scan of abdomen revealed a large right retroperitoneal and psoas muscle hematoma and he underwent surgical exploration to evacuate the hematoma. His condition improved and was discharged well. Although prophylactic anticoagulation may reduce thrombotic complications in severely ill COVID-19 patients, a high index of suspicion for rare bleeding complications should be maintained if patients become hemodynamically unstable. Early diagnosis and appropriate intervention may improve outcome and prevent mortality.
  3. Lee KT, Yeoh WC, Zainul NH, Syed Alwi SB, Low LL
    Med J Malaysia, 2021 09;76(5):653-657.
    PMID: 34508370
    INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic posed a significant and urgent threat to global health and economy. Currently, there is no effective treatment known to alter the course of COVID-19. Convalescent plasma (CP) has been used previously to treat several types of infections during pandemics. The aim of our study is to evaluate the efficacy of CP in the treatment of severe COVID-19 infections at Hospital Sultanah Bahiyah, Kedah, Malaysia.

    MATERIALS AND METHODS: A retrospective cross-sectional study of all severe COVID-19 patients who received CP treatment from 1st August 2020 until 31st December 2020 was conducted. Clinical outcomes were compared before and after CP transfusion.

    RESULTS: Thirty-four patients were enrolled and received CP transfusion during the study period. The most common presenting complaints were fever (64.7%) and cough (58.8%). Fourteen patients showed improvement in oxygen support after CP transfusion. Several laboratory parameters also improved such as increased lymphocyte count (1.48 vs 1.98, p=0.008) and decreased C-reactive protein levels (28.1 vs 10.6, p=0.004), and these were statistically significant. Median time from symptoms onset to CP transfusion was 6 days (range 1-11) while median time from PCR diagnosis to CP transfusion was 5 days (range 1-11). One patient developed urticaria after CP transfusion and no severe adverse events were observed. Two of our patients passed away due to secondary causes.

    CONCLUSION: This study showed CP treatment was well tolerated and could potentially prevent progression of COVID-19 to a severe disease if administered early during the viraemic phase. Further evaluation with randomized control trial should be conducted to help ascertain the optimal dose and effectiveness of CP treatment, in correlation with the IgG titer of the donated CP.

  4. Chaubal TV, Yeoh WC, Phua CKS, Bapat R, Pulikkotil SJ
    Saudi Dent J, 2024 Aug;36(8):1051-1057.
    PMID: 39176154 DOI: 10.1016/j.sdentj.2024.05.011
    BACKGROUND: The placement of immediate dental implants intrinsically displays crestal gaps, which may compromise implant osseointegration. Several grafting materials have been used to overcome this issue. Of the available materials, the use of bone cement is relatively new in oral implantology. This study aimed to examine the available literature on the utilization of bone cements in immediate placement of dental implants and assess its potential in oral implantology.

    OBJECTIVES: To synthesize evidence for appraising the impact of bone cements on implant stability and bone-to-implant contact (BIC) of dental implants placed immediately after extraction in humans and animals after 3 months of healing from tooth extraction.

    METHODS: A systematic search was conducted in PubMed, Medline, and ScienceDirect for relevant studies published from inception to September 2021 using relevant search terms. Of the 1624 studies, 4 were selected for this systematic review.

    RESULTS: Three of the four studies concluded that bone cements enhanced implant stability and/or BIC with better quality and/or quantity of bone surrounding the immediate dental implant. The conclusion drawn by one article remained indecisive. Meta-analysis could not be performed owing to the presence of substantial heterogeneity.

    CONCLUSION: Bone cement is a promising treatment alternative as it augments implant stability and/or BIC in immediate dental implants. Nonetheless, further prospective human clinical trials are required to establish its clinical effectiveness and arrive at a definitive conclusion to recommend its clinical use.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links